Floatz logo

Baricitinib

Baricitinib

The First Affiliated Hospital of University of Science and Technology of ChinaSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Baricitinib cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Baricitinib is also rated in:

long COVID-19Dormant
B
Indicative ·
60 / 100
View asset →
ischemic strokeDormant
B
Indicative ·
57 / 100
View asset →
anterior cerebral artery infarctionDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →